Class I BCS based biowaiver with different amounts of API between T and R [Dissolution / BCS / IVIVC]

posted by Obinoscopy  – USA, 2018-11-10 09:25 (2427 d 23:48 ago) – Posting: # 19560
Views: 3,508

Hi Joose,

❝ Given the API amount difference between T and R do you think a BCS based biowaiver application would still be applicable?


No I don't think so. This is because they are not pharmaceutically equivalent.

This is even stated on the draft ICH M9 Guideline that you referenced. It can be found on lines 121 - 124 where eligibility for BCS based Biowaivers was discussed. Here's the excerpt:

A drug product is eligible for a BCS-based biowaiver provided that the drug substance(s) satisfy the criteria regarding solubility and permeability (BCS Class I and III), the drug product is an immediate-release oral dosage form with systemic action, and the drug product is a dosage form that is pharmaceutically equivalent to the reference product

For two products to be pharmaceutically equivalent, they must be of the same amount. I think some regulatory authorities allow a difference of 5% in the amount. But for 100% difference, no way.

The route you can go would be multiple strength biowaiver. However you have to check that the excipients are in the same proportion with the actives.

Regards

Scopy

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,679 registered users;
86 visitors (0 registered, 86 guests [including 55 identified bots]).
Forum time: 10:14 CEST (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5